Maximus (MMS) Q1 2026 earnings review
Efficiency Trumps Volume: Margins Expand Despite Revenue Dip
Maximus delivered a textbook example of 'doing more with less' in Q1. While revenue fell 4.1% YoY to $1.35B—dragged down by divestitures and the Medicaid unwinding—profitability surged. Adjusted EPS jumped 15% to $1.85, driven by a stellar 16.5% operating margin in the U.S. Federal segment. Management raised full-year earnings guidance significantly, proving that their technology and AI investments are yielding tangible margin benefits. The only blemish was a massive $251M free cash flow burn, attributed to seasonal timing and federal payment delays.
🐂 Bull Case
The U.S. Federal Services segment posted a 16.5% operating margin (vs. 12.7% a year ago). This demonstrates that AI/automation investments are successfully stripping out costs and improving productivity on fixed-price or performance-based contracts.
Despite narrowing revenue expectations, management raised the FY26 Adjusted EPS floor by $0.10 to $8.05-$8.35 and hiked the Adjusted EBITDA margin target to ~14%. This signals high confidence in operational efficiency for the remainder of the year.
🐻 Bear Case
Free Cash Flow was a negative $251M in Q1. While management cites seasonality and administrative delays (DSO spiked to 78 days), this is a significant hole to dig out of to reach the $450-$500M annual target.
The U.S. Services segment is struggling with volume normalization. Revenue dropped 8.2% and margins compressed to 7.1% (from 9.0%). The loss of pandemic-era Medicaid volumes is still weighing heavily on this unit.
⚖️ Verdict: 🟢
Bullish. The margin expansion in the Federal segment is structural and impressive, outweighing the noisy top-line decline caused by divestitures. The cash flow drop is a watch item but appears temporal. The guidance raise in this environment confirms strong execution.
Key Themes
U.S. Federal Segment Dominance
This segment is carrying the company. Revenue grew slightly (+0.8%) against tough comps, but the real story is the margin expansion to 16.5% (+380bps YoY). Management attributes this to 'wider adoption of technology initiatives,' validating their automation strategy. This segment now accounts for ~58% of total revenue but an outsized portion of profit.
Cash Flow & Collection Delays
Free Cash Flow collapsed to -$251M (vs -$103M in 25Q1). Days Sales Outstanding (DSO) deteriorated to 78 days from 62 days last quarter. Management blamed 'administrative delays' and the government shutdown impact. While they maintained full-year FCF guidance ($450-500M), the company needs a massive collection catch-up in Q2-Q4.
Tech-Enabled Efficiency (AI)
Management explicitly linked margin improvements to AI and automation: 'expanding the use of automation, including AI... to support productivity and margins.' This is no longer just a talking point; it is visible in the P&L, specifically in the 12.7% Adjusted EBITDA margin achieved despite revenue pressure.
International Struggles
The 'Outside the U.S.' segment swung to an operating loss of $1.4M (vs. +$8.1M profit YoY). Revenue fell to $143M due to divestitures (Australia/South Korea). While the divestitures were strategic to remove volatility, the remaining business is currently dragging on consolidated income due to business development costs and delayed new work.
Medicaid Unwinding Headwind
U.S. Services revenue dropped 8.2% YoY. The company is lapping periods that benefited from the Medicaid redetermination (unwinding) volumes. Margins in this segment (7.1%) are well below the full-year target of ~10.5-11%, indicating the segment is currently sub-scale relative to its fixed cost base.
Working Families Tax Cut Act
Management highlighted expanding opportunities related to the 'Working Families Tax Cut Act' as a pipeline driver. This suggests future legislative tailwinds could replace the Medicaid unwinding volume vacuum.
Other KPIs
Accelerating. Up 15% YoY from $1.61. Beat the narrative of revenue decline. Driven by margin expansion and a lower share count (55.3M diluted shares vs 60.0M YoY) due to buybacks.
Decelerating/Concern. Down from 9.0% YoY and 9.7% in 25Q4. This is significantly below the FY26 guidance range of 10.5% - 11%, implying a steep ramp-up is required in the remaining quarters.
Stable/Growing. Up from $51.3B reported at FY25 year-end. New work opportunities represent 59% of the pipeline, suggesting healthy demand despite federal delays.
Guidance
Stable/Narrowed. The range was tightened from $5.225-$5.425B. The midpoint ($5.275B) implies a ~2.9% decline vs FY25 ($5.43B), reflecting the divestiture of ~$100M in revenue and normalizing volumes.
Accelerating. Guidance raised from prior $7.95-$8.25. The midpoint ($8.20) implies 11.4% growth over FY25 ($7.36), despite lower revenue. Driven by margin expansion to ~14%.
Stable. Guidance maintained despite the -$251M Q1 outflow. This implies the company must generate ~$725M in FCF over the next three quarters, placing high pressure on collections.
Accelerating. Raised from prior view of 15.5%-16%. Management is banking the Q1 beat (16.5%) and projecting continued efficiency.
Key Questions
Cash Flow Recovery Viability
You burned $251M in Q1 but maintained full-year FCF guidance of $450-500M. This requires generating ~$725M in 9 months. What specific large payments are unlocked, and what is the risk of further delays?
International Profitability Timeline
The 'Outside U.S.' segment posted a loss this quarter. With the divestitures complete, why are business development costs still outweighing revenue, and when does this segment turn EBITDA positive?
U.S. Services Margin Ramp
U.S. Services margin was 7.1% in Q1, but guidance is 10.5%-11%. That is a massive step up for a shrinking segment. What specific volume drivers or cost cuts hit in Q2-Q4 to bridge this gap?